Actinogen acquires Edinburgh BioQuarter spin-out Corticrine

31 October 2014

Australian biotech firm Actinogen (ASX: ACW) has acquired Edinburgh BioQuarter spin-out, Corticrine. Financial terms of the transaction were not disclosed.

Corticrine is a mid-stage pharmaceutical R&D company focused on the development of novel treatments for disease modification and prevention in Alzheimer’s dementia. It is a spin-out company from the Edinburgh BioQuarter, the commercialization arm of the College of Medicine and Veterinary Medicine of the University of Edinburgh.

Corticrine has licensed worldwide development and commercialization rights to UE2323 from the University of Edinburgh. UE2343 is in clinical development for the treatment of Alzheimer’s disease and has already received considerable funding for the Wellcome Trust Seeding Drug Discovery Program.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK